Table 6.
Patient daily dose and defined daily dose of OROS-MPH among all adult patients with diagnosed ADHD treated with OROS-MPH during the study period (cross-sectional dataset; 2006–2011)
| Mean (SD) patient daily dose, mg | Defined daily dose, mg | 95% confidence limits (mg) | |
|---|---|---|---|
| Total (n=21,926) | 51.5 (31.0) | 1.72 | 51.1, 51.9 |
| Males (n=12,025) | 54.4 (33.3)a | 1.81 | 53.8, 55.0 |
| Females (n=9,901) | 47.9 (27.7) | 1.60 | 47.4, 48.5 |
| Age group | |||
| 18–21 years (n=4,942) | 42.9 (21.5)b | 1.43 | 42.3, 43.5 |
| 22–64 years (n=16,930) | 53.9 (32.9) | 1.80 | 53.5, 54.4 |
| ≥65 years (n=54) | 53.5 (34.9) | 1.78 | 44.0, 63.1 |
Notes:
p<0.05 for comparison with females.
p<0.05 for comparisons with 22–64 years and ≥65 years. The patient daily dose is the average daily amount of a drug that is actually prescribed. The defined daily dose is the assumed average maintenance dose per day for a drug used for its main indication in adults.31 The independent t-test was used to identify potential statistical differences in the mean dose between sexes, and analysis of variance was used to identify potential statistical differences in the mean dose between age groups.
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; OROS-MPH, osmotic release oral system methylphenidate.